Late-stage optimization of a tercyclic class of S1P3-sparing, S1P1 receptor agonists.

Joshua C Horan,Daniel Kuzmich,Pingrong Liu,Darren DiSalvo,John Lord,Can Mao, Tamara D Hopkins,Hui Yu,Christian Harcken,Raj Betageri,Melissa Hill-Drzewi,Lori Patenaude,Monica Patel,Kimberly Fletcher,Donna Terenzzio,Brian Linehan,Heather Xia,Mita Patel, Debbie Studwell,Craig Miller,Eugene Hickey, Jeremy I Levin, Dustin Smith,Raymond A Kemper,Louise K Modis,Lynne C Bannen,Diva S Chan,Morrison B Mac,Stephanie Ng,Yong Wang,Wei Xu,René M Lemieux

Bioorganic & Medicinal Chemistry Letters（2016）

Cited 0|Views10

No score

Abstract

Poor solubility and cationic amphiphilic drug-likeness were liabilities identified for a lead series of S1P3-sparing, S1P1 agonists originally developed from a high-throughput screening campaign. This work describes the subsequent optimization of these leads by balancing potency, selectivity, solubility and overall molecular charge. Focused SAR studies revealed favorable structural modifications that, when combined, produced compounds with overall balanced profiles. The low brain exposure observed in rat suggests that these compounds would be best suited for the potential treatment of peripheral autoimmune disorders.

Translated text

Key words

SFBFJQXHRYGKHV-INIZCTEOSA-N,SDCQNJRPSLMFIT-SFHVURJKSA-N,GMEODUAZQQLOFF-MRXNPFEDSA-N,MUINZQQLLPFAQS-OAHLLOKOSA-N

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined